How Does Legend Biotech Company Work?

How has Legend Biotech reshaped CAR-T treatment outcomes?

Legend Biotech rose quickly after launching Carvykti, reaching an estimated $2,000,000,000 in annual net trade sales by early 2025 and securing a mid-teen billion valuation through strategic partnerships and scaled manufacturing.

Legend operates via a partnership model—most notably with Janssen—combining in-house R&D, specialized autologous manufacturing, and revenue-sharing to commercialize CAR-T at scale; see Legend Biotech Porter's Five Forces Analysis for strategic context.

Legend Biotech creates value by developing autologous CAR-T therapies that reprogram a patient’s T cells to target cancer, centered on a proprietary BCMA-targeting platform and a vein-to-vein manufacturing model that demands tight clinical and supply-chain coordination.

Vein-to-vein manufacturing

Leukapheresis at clinic sites, cryogenic transport, centralized genetic modification, and return shipment for infusion form the end-to-end flow that defines Legend Biotech operations.

BCMA dual-epitope binding

The dual-epitope binding strategy targets two sites on BCMA to potentially improve response depth and durability versus single-epitope approaches.

Global manufacturing network

Key manufacturing hubs in Raritan, New Jersey, and Ghent, Belgium use automated closed-system processing to support high-touch, low-volume personalized products and reduce contamination risk.

Commercial partnership

Partnering with Janssen provides commercial infrastructure and distribution reach across North America, Europe, and Greater China to scale patient access.

The operational model blends specialized manufacturing capacity with clinical logistics, quality systems, and regulatory pathways to support approvals and commercialization of its lead BCMA CAR T-cell therapy.

Operational highlights and metrics

Key operational and commercial facts as of 2025 underpinning Legend Biotech's value proposition.

• 2 major GMP hubs: Raritan, NJ and Ghent, Belgium handling autologous manufacturing.
• Vein-to-vein cycle time targets commonly range from 2–4 weeks depending on logistics and patient conditioning.
• Dual-epitope BCMA binding aims to increase response durability observed in clinical cohorts versus historic single-epitope data.
• Strategic commercialization with Janssen expands market access; see Revenue Streams & Business Model of Legend Biotech for related business model details.

Revenue Streams and Monetization Strategies center on Carvykti commercial sales, collaboration milestones, licensing and R&D cost-sharing that together shift Legend Biotech operations from capital raises to self-funded pipeline expansion.

Primary commercial revenue

Carvykti sales are the core cash driver under a global profit-and-loss sharing model with Janssen, excluding Greater China where Legend keeps a larger share.

Profit-share structure

The company operates a 50-50 P&L split with Janssen worldwide except Greater China, where Legend retains 70% of profits.

Revenue growth trend

Net trade sales for Carvykti grew exponentially in FY2024 into 2025, with quarterly revenues consistently above $450,000,000.

Milestone and licensing income

One-time collaboration milestones tied to regulatory approvals and cumulative sales targets provide significant lump-sum payments.

R&D cost reimbursement

Partners reimburse portions of ongoing R&D, supporting Legend Biotech CAR T-cell therapy pipeline progression and platform development.

Long-term IP monetization

Commercial margins from Carvykti fund solid tumor programs and allogeneic CAR-T work, building licensable intellectual property and future revenue streams.

Key monetization elements in Legend Biotech's business model combine near-term product cash flow with strategic partnerships and licensing to support pipeline capital needs and diversify income.

Revenue composition and strategic levers

Revenue mix emphasizes product sales, milestone receipts, and partner-funded R&D with scalability plans for broader indications and geographies.

• Product sales: Carvykti net trade sales — quarterly > $450,000,000 in 2024–2025
• Profit-share: 50-50 global P&L with Janssen; 70% retained in Greater China
• Milestones: regulatory and sales-triggered lump-sum payments
• Licensing/R&D: cost-sharing and future IP licensing for allogeneic and solid tumor platforms

Mission, Vision & Core Values of Legend Biotech

Key milestones for Legend Biotech include the 2024 FDA and EMA approvals expanding Carvykti to second-line use and the 2025 Obelisc facility ramp-up with Janssen, tripling global manufacturing capacity to meet demand; strategic moves emphasize capacity expansion, faster turnaround and pipeline diversification to sustain competitive advantage.

Regulatory Breakthroughs

In 2024 Carvykti gained FDA and EMA approval for second-line and beyond based on CARTITUDE-4, moving the therapy into standard of care for relapsed patients and expanding the eligible population significantly.

Manufacturing Scale-Up

Legend and Janssen declared Obelisc in Belgium fully operational in 2025, tripling production capacity and directly addressing the CAR-T manufacturing slot shortage that constrained market growth.

Clinical Differentiation

Carvykti has shown superior overall response rates and longer progression-free survival versus the primary competitor in cross-trial and indirect comparisons, reinforcing Legend Biotech operations around strong clinical data.

Platform & Pipeline

Legend maintains technological leadership via the proprietary LCAR-B38M platform and exploration of GPRC5D-targeted therapies, supporting a diversified Legend Biotech pipeline beyond B-cell malignancies.

Operational focus has been on shortening manufacturing turnaround times to an average of 3 to 4 weeks, improving patient-centric logistics and building a durable competitive moat based on efficacy and supply reliability rather than first-mover status.

Strategic Risks & Financial Context

Key risks include reimbursement dynamics, pricing pressure, and potential competitor pipeline advances; 2025 production scale and broader label support aim to bolster revenue growth and capacity-driven margin improvement.

• Regulatory: 2024 approvals extended the label, shifting market penetration dynamics
• Manufacturing: Obelisc tripled capacity to address bottlenecks and lower lead times
• Clinical: Carvykti shows superior response and PFS versus Abecma in available comparisons
• Technology: Continued development of GPRC5D programs and LCAR-B38M platform expands therapeutic scope

For context on market positioning and target segments see Target Market of Legend Biotech, which complements this overview of how Legend Biotech functions and its business model.

As of early 2025, Legend Biotech operations command a leading position in BCMA CAR-T, with an estimated 60 percent share in relapsed/refractory multiple myeloma; the company balances this dominance against regulatory, pricing, and safety risks while pursuing diversification into solid tumors and allogeneic approaches.

Market Position

Legend Biotech business model centers on its BCMA CAR T-cell therapy franchise, capturing roughly 60% of the relapsed/refractory myeloma market by early 2025 and reporting record 2025 revenues that strengthened its balance sheet.

Regulatory Risks

FDA scrutiny of long-term CAR-T safety, particularly potential secondary malignancies, forces extensive post-marketing surveillance and long-term follow-up studies for risk mitigation and label compliance.

Pricing and Payer Pressure

With per-dose therapy costs often exceeding $450,000, Legend faces pricing pressure from government payers and potential impacts from the Inflation Reduction Act drug negotiation provisions in the United States.

Diversification Strategy

The development roadmap targets solid tumors such as small cell lung cancer and gastric cancer and a strategic pivot to allogeneic off-the-shelf therapies to reduce cost and manufacturing lead time.

Legend Biotech's technology platform and pipeline aim to transition the company from a single-product specialty to a multi-product oncology player by 2026, supported by strong cash flow and sustained R&D investment.

Risks, Metrics, and Strategic Priorities

Key operational and investor considerations combine clinical, regulatory, commercial, and manufacturing factors that will shape near-term performance and long-term valuation.

• Safety surveillance: mandatory long-term follow-up for secondary malignancy risk under FDA post-marketing requirements
• Cost dynamics: therapy pricing above $450,000 per dose creates exposure to reimbursement cuts and negotiation under the Inflation Reduction Act
• Manufacturing scale: move toward allogeneic platforms aims to cut per-patient manufacturing costs and reduce wait times versus autologous processes
• Pipeline expansion: advancing programs in solid tumors could address larger patient populations and diversify revenue streams by 2026

Further context on competitive positioning and partnerships is available in this market review Competitors Landscape of Legend Biotech.